Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1989 2
1990 3
1991 3
1994 1
1995 2
1996 2
1997 8
1998 15
1999 28
2000 44
2001 23
2002 31
2003 27
2004 25
2005 26
2006 30
2007 38
2008 39
2009 36
2010 42
2011 38
2012 35
2013 42
2014 43
2015 41
2016 33
2017 31
2018 27
2019 32
2020 32
2021 18
2022 14
2023 27
2024 19
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

785 results

Results by year

Filters applied: . Clear all
Page 1
Ropinirole.
Rewane A, Patel P, Nagalli S. Rewane A, et al. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32119419 Free Books & Documents.
Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. ...This mechanism maximizes the "on" time and minimizes the "off" time associated with disease progression, making ropinirole an attractive option for m …
Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. ...This mechanism m …
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, Nakamura S, Ozawa F, Chyi CM, Nishiyama A, Suzuki N, Fujimori K, Kondo T, Takao M, Hirai M, Kabe Y, Suematsu M, Jinzaki M, Aoki M, Fujiki Y, Sato Y, Suzuki N, Nakahara J; Pooled Resource Open-Access ALS Clinical Trials Consortium; Okano H. Morimoto S, et al. Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Free article. Clinical Trial.
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole or placebo for 24 weeks in the double-blind period to evaluate safety, tolerability, and therapeutic effects. ...However, in the open-labe …
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole …
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS, Oztekin N, Oztekin MF. Gencler OS, et al. Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039. Ideggyogy Sz. 2022. PMID: 35112520 Free article. Clinical Trial. English.
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropinirole. The maximum daily dosages of pramipexole and ropinirole were 4.5 mg and 24 mg respectively. ...CONCLUSION: This study suppo …
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropini …
Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease.
Naz F, Rahul, Fatima M, Naseem S, Khan W, Mondal AC, Siddique YH. Naz F, et al. Neuropharmacology. 2020 Oct 15;177:108216. doi: 10.1016/j.neuropharm.2020.108216. Epub 2020 Jul 21. Neuropharmacology. 2020. PMID: 32707222 Review.
The present study investigates the neuro-protective role of synthesized ropinirole silver nanocomposite (RPAgNC) in Drosophila model of PD. alpha-synuclein accumulation in the brain of flies (PD flies) leads to the damage of dopaminergic neurons, dopamine dep …
The present study investigates the neuro-protective role of synthesized ropinirole silver nanocomposite (RPAgNC) in Drosophila model …
Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ, Spencer CM. Matheson AJ, et al. Drugs. 2000 Jul;60(1):115-37. doi: 10.2165/00003495-200060010-00007. Drugs. 2000. PMID: 10929932 Review.
Ropinirole is indicated as adjunct therapy to levodopa in patients with advanced Parkinson's disease. ...Ropinirole was well tolerated either as monotherapy or as an adjunct to levodopa treatment. ...
Ropinirole is indicated as adjunct therapy to levodopa in patients with advanced Parkinson's disease. ...Ropinirole was well t …
Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel MD. Kuzel MD. Am J Health Syst Pharm. 1999 Feb 1;56(3):217-24. doi: 10.1093/ajhp/56.3.217. Am J Health Syst Pharm. 1999. PMID: 10030505 Review.
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, and formulary considerations of ropinirole are reviewed. ...Ropinirole was as effective as levodopa in patients with earlier stages of PD. In one subset …
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, and formulary considerations of …
Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease.
Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Hattori N, et al. Mov Disord. 2020 Sep;35(9):1565-1573. doi: 10.1002/mds.28071. Epub 2020 May 12. Mov Disord. 2020. PMID: 32396257 Clinical Trial.
METHODS: PD patients using levodopa received ropinirole patch (up to 64 mg/d), ropinirole tablets (up to 16 mg/d), or placebo once-daily (double-dummy technique). ...Ropinirole patch can be an alternative option for PD patients. 2020 Internation …
METHODS: PD patients using levodopa received ropinirole patch (up to 64 mg/d), ropinirole tablets (up to 16 mg/d), or p …
Ropinirole suppresses LPS-induced periodontal inflammation by inhibiting the NAT10 in an ac4C-dependent manner.
Liao H, Ma H, Meng H, Kang N, Wang L. Liao H, et al. BMC Oral Health. 2024 Apr 30;24(1):510. doi: 10.1186/s12903-024-04250-5. BMC Oral Health. 2024. PMID: 38689229 Free PMC article.
METHODS: Human gingival fibroblasts (HGFs) treated with LPS were considered to mimic periodontitis in vitro. The dosage of Ropinirole was selected through the cell viability of HGFs evaluation. The protective effects of Ropinirole on HGFs were evaluated by detecting …
METHODS: Human gingival fibroblasts (HGFs) treated with LPS were considered to mimic periodontitis in vitro. The dosage of Ropinirole …
Ropinirole treatment for restless legs syndrome.
Chitnis S. Chitnis S. Expert Opin Drug Metab Toxicol. 2008 May;4(5):655-64. doi: 10.1517/17425255.4.5.655. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484922 Review.
Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements; and on subjective measures of sleep, ropinirole was genera …
Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on …
Clinical pharmacokinetics of ropinirole.
Kaye CM, Nicholls B. Kaye CM, et al. Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001. Clin Pharmacokinet. 2000. PMID: 11069211 Review.
Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. ...There is no obvious plasma concentration-effect relationship for ropinirole....
Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. ...There is no …
785 results